149 related articles for article (PubMed ID: 15526541)
1. Effects of Atorvastatin on some inflammatory parameters in severe primary hypercholesterolemia.
Dobreanu M; Gălăţeanu C; Simionescu A; Deac R
Rom J Intern Med; 2002; 40(1-4):61-73. PubMed ID: 15526541
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
3. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
4. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
7. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
8. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
Kuryata OV; Yegorova YV
Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
[TBL] [Abstract][Full Text] [Related]
9. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Betteridge DJ; Gibson JM; Sager PT
Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy.
Sampietro T; Bigazzi F; Rossi G; Dal Pino B; Puntoni MR; Sbrana F; Chella E; Bionda A
J Intern Med; 2005 Jun; 257(6):523-30. PubMed ID: 15910556
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
13. Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin.
Dobreanu M; Dobreanu D; Fodor A; Bacarea A
Rom J Intern Med; 2007; 45(2):193-9. PubMed ID: 18333374
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
15. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
[TBL] [Abstract][Full Text] [Related]
16. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
17. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
Ushiroyama T; Nosaka S; Ueki M
Int J Cardiol; 2006 Oct; 113(1):66-75. PubMed ID: 16356567
[TBL] [Abstract][Full Text] [Related]
18. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia.
Nawawi H; Osman NS; Yusoff K; Khalid BA
Horm Metab Res; 2003 Aug; 35(8):479-85. PubMed ID: 12953165
[TBL] [Abstract][Full Text] [Related]
19. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
